IMU.ASX: Quarterly Activities/Appendix 4C Cash Flow Report

Quarterly Activities/Appendix 4C Cash Flow Report

Stock	Imugene Ltd (IMU.ASX)
Release Time	31 Jul 2026, 9:12 a.m.
Price Sensitive	Yes

This feature provides summaries of price-sensitive announcements for companies followed by users on InvestorPA. The summaries are generated by large language models so please interpret with care.

Imugene Reports Quarterly Activities and Cash Flows

Key Points

Promising initial data in the Concurrent BTKi Cohort of azer-cel Phase 1b Trial
FDA grants Fast Track Designation for azer-cel in two additional indications
Board strengthened with appointment of two new non-executive directors
Post 30 June, $11.12 million raised from sophisticated, professional and institutional investors
CEO resignation and search for new leadership underway

Full Summary

Imugene Limited (ASX: IMU) has released its Quarterly Activities and Cash Flow report for the quarter ended 30 June 2026. The report highlights promising initial data from the Concurrent BTKi Cohort of the azer-cel Phase 1b trial, with complete and partial responses reported. The FDA granted Fast Track Designation for azer-cel in two additional indications: relapsed or refractory Chronic Lymphocytic Leukaemia / Small Lymphocytic Lymphoma (CLL/SLL) and Marginal Zone Lymphoma (MZL). The company also announced the appointment of two new non-executive directors to its board. Post quarter-end, Imugene completed a $11.12 million capital raise through a two-tranche placement. Additionally, the company announced the resignation of its CEO, Leslie Chong, and has initiated a search for new leadership.